These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36403729)

  • 1. Letter to the Editor: Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
    Yao M; Lu F
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2697-2698. PubMed ID: 36403729
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
    Lefere S; Dupont E; De Guchtenaere A; Van Biervliet S; Vande Velde S; Verhelst X; Devisscher L; Van Vlierberghe H; Geerts A; De Bruyne R
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2317-2326.e4. PubMed ID: 34871812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
    Feng Y; Peng B; Li Y; Sun L; Sun Y
    Hepatology; 2023 May; 77(5):E103-E104. PubMed ID: 36645222
    [No Abstract]   [Full Text] [Related]  

  • 4. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
    Crespo M; Lappe S; Feldstein AE; Alkhouri N
    Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Cheema MRS
    Hepatology; 2023 Jul; 78(1):E18. PubMed ID: 37054978
    [No Abstract]   [Full Text] [Related]  

  • 6. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.
    Noureddin M; Chan JL; Barradas K; Dimick-Santos L; Schabel E; Omokaro SO; Anania FA; Myers RP; Miller V; Sanyal AJ; Chalasani N;
    Gastroenterology; 2020 Aug; 159(2):422-427.e1. PubMed ID: 32353369
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".
    Liu Y; Chen M
    Clin Mol Hepatol; 2023 Jan; 29(1):163-164. PubMed ID: 36300328
    [No Abstract]   [Full Text] [Related]  

  • 8. Correspondence on Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".
    Lee SM; Jun DW
    Clin Mol Hepatol; 2023 Jan; 29(1):171-172. PubMed ID: 36353765
    [No Abstract]   [Full Text] [Related]  

  • 9. Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease.
    Fleet SE; Lefkowitch JH; Lavine JE
    Gastroenterol Clin North Am; 2017 Jun; 46(2):217-231. PubMed ID: 28506362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
    Kleiner DE; Makhlouf HR
    Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians.
    Yadav Y; Syn WK; Basu R
    Diabetes Technol Ther; 2019 Nov; 21(11):611-618. PubMed ID: 31335197
    [No Abstract]   [Full Text] [Related]  

  • 14. The Evolving Role of Liver Biopsy in Non-alcoholic Fatty Liver Disease.
    Arab JP; Barrera F; Arrese M
    Ann Hepatol; 2018 Oct; 17(6):899-902. PubMed ID: 30600304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.
    Hashem A; Khalouf A; Acosta A
    Semin Liver Dis; 2021 Nov; 41(4):435-447. PubMed ID: 34243193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease.
    Isaacs S
    Endocrinol Metab Clin North Am; 2023 Mar; 52(1):149-164. PubMed ID: 36754491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter to the editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Kumar A; Sharma P; Arora A
    Hepatology; 2022 Jul; 76(1):E3-E4. PubMed ID: 35092319
    [No Abstract]   [Full Text] [Related]  

  • 18. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histopathological diagnosis and differential diagnosis of nonalcoholic fatty liver disease].
    Theurer S; Kälsch J; Schwertheim S; Kathemann S; Baba HA
    Pathologe; 2020 Sep; 41(5):434-443. PubMed ID: 32533233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.